ProTECTIII Study

The results from the ProTECTIII trial comparing intravenous progesterone to placebo for the treatment of a moderate to severe traumatic brain injury (TBI) are out. While traumatic brain injury (TBI) is a huge problem, an estimated 52,000 people will die every year from one and cost Americans tens of billions of dollars a year between treatment and disability, scientists have not been able to come up with a drug treatment that works for TBI in over 30 years. Disappointingly, the ProTECT results published in the December 10, 2014 issue of the New England Journal of Medicine show that the treatment of acute traumatic brain injury with the hormone progesterone provides no significant benefit to patients when compared with placebo. The preclinical data on progesterone’s brain protective effects are compelling, but we were not able to show this in a large trial with human traumatic brain injury. To learn more about the ProTECT trial results visit the ProTECT website at: [www.protectiii.com](http://www.protectiii.com)